Open AccessMeta‐analysis of the molecular associations of mucinous colorectal cancer
Author(s) -
Reynolds I. S.,
Furney S. J.,
Kay E. W.,
McNamara D. A.,
Prehn J. H. M.,
Burke J. P.
Publication year - 2019
Publication title -
british journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.202
H-Index - 201
eISSN - 1365-2168
pISSN - 0007-1323
DOI - 10.1002/bjs.11142
Subject(s) - kras , colorectal cancer , microsatellite instability , medicine , adenocarcinoma , oncology , mlh1 , mucinous carcinoma , gastroenterology , odds ratio , cancer , dna mismatch repair , microsatellite , allele , genetics , biology , gene
Background Mucinous differentiation occurs in 5–15 per cent of colorectal adenocarcinomas. This subtype of colorectal cancer responds poorly to chemoradiotherapy and has a worse prognosis. The genetic aetiology underpinning this cancer subtype lacks consensus. The aim of this study was to use meta‐analytical techniques to clarify the molecular associations of mucinous colorectal cancer. Methods This study adhered to MOOSE guidelines. Databases were searched for studies comparing KRAS , BRAF , microsatellite instability (MSI), CpG island methylator phenotype (CIMP), p53 and p27 status between patients with mucinous and non‐mucinous colorectal adenocarcinoma. A random‐effects model was used for analysis. Results Data from 46 studies describing 17 746 patients were included. Mucinous colorectal adenocarcinoma was associated positively with KRAS (odds ratio (OR) 1·46, 95 per cent c.i. 1·08 to 2·00, P = 0·014) and BRAF (OR 3·49, 2·50 to 4·87; P < 0·001) mutation, MSI (OR 3·98, 3·30 to 4·79; P < 0·001) and CIMP (OR 3·56, 2·85 to 4·43; P < 0·001), and negatively with altered p53 expression (OR 0·46, 0·31 to 0·67; P < 0·001). Conclusion The genetic origins of mucinous colorectal adenocarcinoma are predominantly associated with BRAF , MSI and CIMP pathways. This pattern of molecular alterations may in part explain the resistance to standard chemotherapy regimens seen in mucinous adenocarcinoma.